PDF下载 ( 1516 KB)
Role of circulating microRNAs in development and progression of liver fibrosis
-
摘要:
MiroRNA(miRNA)可通过外泌体等载体分泌,游离于细胞之外,并可在循环血液中保持稳定状态。目前研究表明,循环血中miRNA的变化趋势与疾病的不同病理状态相关,提示循环血中miRNA可作为疾病潜在的诊断和治疗分子靶标。研究表明多种miRNA与肝纤维化的发生发展密切相关,概述了目前关于肝纤维化进程中循环血miRNA表达差异的研究,多种研究提示循环血miRNA可为肝纤维化的无创性早期诊断和治疗提供新的研究方向。
Abstract:Recent studies have found that microRNAs( miRNAs) can be secreted via exosomes,stay outside the cells,and keep stable in circulating blood. Various studies have shown that the changes in circulating miRNAs are associated with different pathological states,suggesting that the circulating miRNAs can be used as potential molecular targets for the diagnosis and treament of diseases. Research has shown that miRNAs are closely associated with the development and progression of liver fibrosis. This article reviews the studies on the differences in the expression of circulating miRNAs in the course of liver fibrosis and points out that circulating microRNAs can provide a new research direction for early noninvasive diagnosis and treatment of liver fibrosis.
-
Key words:
- liver cirrhosis /
- microRNAs /
- review
-
[1]LAWRIE CH,GAL S,DUNLOP HM,et al.Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma[J].Br J Haematol,2008,141(5):672-675. [2]CARVALHO INSR,FREITAS RM,VARGAS FR.Translating microRNAs into biomarkers:What is new for pediatric cancer?[J].Med Oncol,2016,33(5):49. [3]LI A,YU J,KIM HY,et al.MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls.[J].Clin Cancer Res,2013,19(13):3600-3610. [4]KJERSEM JB,IKDAHL T,LINGJAERDE OC,et al.Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment[J].Mol Oncol,2014,8(1):59-67. [5]GALLO A,TANDON M,ALEVIZOS I,et al.The majority of microRNAs detectable in serum and saliva is concentrated in exosomes[J].PLo S One,2012,7(3):e30679. [6]FUJITA Y,YOSHIOKA Y,OCHIYA T.Extracellular vesicle transfer of cancer pathogenic components[J].Cancer Sci,2016,107(4):385-390. [7]STREMERSCH S,VANDENBROUCKE RE,van WONTERGHEM E,et al.Comparing exosome-like vesicles with liposomes for the functional cellular delivery of small RNAs[J].J Control Release,2016,232:51-61. [8]COENEN-STASS AM,MAGER I,WOOD MJ.Extracellular microRNAs in membrane vesicles and non-vesicular carriers[J].EXS,2015,106:31-53. [9]ZHANG QQ,XU MY,QU Y,et al.Analysis of the differential expression of circulating microRNAs during the progression of hepatic fibrosis in patients with chronic hepatitis B virus infection[J].Mol Med Rep,2015,12(4):5647-5654. [10]ARROYO JD,CHEVILLET JR,KROH EM,et al.Argonaute2complexes carry a population of circulating microRNAs independent of vesicles in human plasma[J].Proc Natl Acad Sci U S A,2011,108(12):5003-5008. [11]VICKERS KC,PALMISANO B,TSHOUCRI BM,et al.MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins[J].Nat Cell Biol,2011,13(4):423-433. [12]GUO CJ,PAN Q,LI DG,et al.MiR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell:an essential role for apoptosis[J].J Hepatol,2009,50(4):766-778. [13]JI J,ZHANG J,HUANG G,et al.Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation[J].FEBS Lett,2009,583(4):759-766. [14]PIROLA CJ,GIANOTTI TF,CASTANO GO,et al.Circulating microRNA signature in non-alcoholic fatty liver disease:from serum non-coding RNAs to liver histology and disease pathogenesis[J].Gut,2015,64(5):800-812. [15]CSAK T,BALA S,LIPPAI D,et al.MicroRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis[J].Liver Int,2015,35(2):532-541. [16]BUTT AM,RAJA AJ,SIDDIQUE S,et al.Parallel expression profiling of hepatic and serum microRNA-122 associated with clinical features and treatment responses in chronic hepatitis C patients[J].Sci Rep,2016,6:21510. [17]WAIDMANN O,KOBERLE V,BRUNNER F,et al.Serum microRNA-122 predicts survival in patients with liver cirrhosis[J].PLo S One,2012,7(9):e45652. [18]ARATAKI K,HAYES CN,AKAMATSU S,et al.Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B[J].J Med Virol,2013,85(5):789-798. [19]NOVELLINO L,ROSSI R,BONINO F,et al.Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs[J].PLo S One,2012,7(3):e31952. [20]ANADOL E,SCHIERWAGEN R,ELFIMOVA N,et al.Circulating microRNAs as a marker for liver injury in human immunodeficiency virus patients[J].Hepatology,2015,61(1):46-55. [21]RODERBURG C,URBAN GW,BETTERMANN K,et al.MicroRNA profiling reveals a role for miR-29 in human and murine liver fibrosis[J].Hepatology,2011,53(1):209-218. [22]KWIECINSKI M,ELFIMOVA N,NOETEL A,et al.Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29[J].Lab Invest,2012,92(7):978-987. [23]ZHANG YQ,WU LP,WANG Y,et al.Protective role of estrogen-induced miRNA-29 expression in carbon tetrachloride-induced mouse liver injury[J].J Biol Chem,2012,287(18):14851-14862. [24]CHEN YJ,ZHU JM,WU H,et al.Circulating microRNAs as a fingerprint for liver cirrhosis[J].PLo S One,2013,8(6):e66577. [25]WANG BC,LI WX,GUO K,et al.miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients[J].Biochem Biophys Res Commun,2012,421(1):4-8. [26]YU FJ,GUO Y,CHEN BC,et al.MicroRNA-17-5p activates hepatic stellate cells through targeting of Smad7[J].Lab Invest,2015,95(7):781-789. [27]ZHENG JJ,ZHOU ZX,XU ZQ,et al.Serum microRNA-125a-5p,a useful biomarker in liver diseases,correlates with disease progression[J].Mol Med Rep,2015,12(1):1584-1590. [28]EL-AHWANY E,NAGY F,ZOHEIRY M,et al.Circulating miRNAs as predictor markers for activation of hepatic stellate cells and progression of HCV-induced liver fibrosis[J].Electronic Physician,2016,8(1):1804-1810. [29]SHRIVASTAVA S,PETRONE J,STEELE R,et al.Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression[J].Hepatology,2013,58(3):863-871. [30]XIE Y,YAO QW,BUTT AM,et al.Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis,liver cirrhosis,and hepatocellular carcinoma[J].Cancer Biol Ther,2014,15(9):1248-1255. [31]TU XL,ZHANG HY,ZHANG JC,et al.MicroRNA-101 suppresses liver fibrosis by targeting the TGFbeta signalling pathway[J].J Pathol,2014,234(1):46-59. [32]BENZ F,RODERBURG C,CARDENAS DV,et al.U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis[J].Exp Mol Med,2013,45:e42. [33]LI Y,ZHANG L,LIU F,et al.Identification of endogenous controls for analyzing serum exosomal miRNA in patients with hepatitis B or hepatocellular carcinoma[J].Dis Markers,2015,2015:893594. [34]WANG K,YUAN Y,CHO JH,et al.Comparing the MicroRNA spectrum between serum and plasma[J].PLo S One,2012,7(7):e41561. -
本文二维码
计量
- 文章访问数: 1912
- HTML全文浏览量: 13
- PDF下载量: 433
- 被引次数: 0
下载:
